Publikationen 2020-

2024

• Implementation of an Immunoassay Based on the MVA-T7pol-Expression System for Rapid Identification of Immunogenic SARS-CoV-2 Antigens: A Proof-of-Concept Study.
  Kumar S., Nan L., Kalodimou G., Jany S., Freudenstein A., Brandmüller C., Müller K., Girl P., Ehmann R., Guggemous W., Seilmaier M., Wendtner C.-M., Volz A., Sutter G., Fux R., Tscherne A.
  Int J Mol Sci. 2024, Oct 10;25(20):10898. doi: 10.3390/ijms252010898

2023

• Short- and Long-Interval Prime-Boost Vaccination with the Candidate Vaccines MVA-SARS-2-ST and MVA-SARS-2-S Induces Comparable Humoral and Cell-Mediated Immunity in Mice.
  Kalodimou G., Jany S., Freudenstein A., Schwarz J.H., Limpinsel L., Rohde C., Kupke A., Becker S., Volz A., Tscherne A., Sutter G.
  Viruses. 2023 May 17;15(5):1180. doi:10.3390/v15051180. PMID: 37243266; PMCID: PMC10222707.
  

2022

• Stabilized recombinant SARS-CoV-2 spike antigen enhances vaccine immmunogenicity and protective capacity.
  Meyer zu Natrup C., Tscherne A., Dahlke C., Ciurkiewicz M., Shin D.-l., Fathi A., Rohde C., Kalodimou G., Halwe S., Limpinsel L., Schwarz J.H., Klug M., Esen M., Schneiderhan-Marra N., Dulovic A., Kupke A., Brosinski K, Clever S, Schünemann L.-M., Beythien G., Armando F., Mayer L., Weskamm L.M., Jany S., Freudenstein A., Tuchel T., Baumgärtner W., Kremsner P., Fendel R., Addo M.M., Becker S., Sutter G., Volz A.
  J Clin Invest. 2022 Oct 27; e159895. doi: 10.1172/JCI159895.
• Increased neutralization and IgG epitope identification aftre MVA-MERS-S booster vaccination against Middle East respiratory syndrome.
  Fathi A., Dahlke C., Krähling V., Kupke A., Okba N.M.A., Raadsen M.P., Heidepriem J., Müller M.A., Paris G., Lassen S., KLüver M., Volz A., Koch T., Ly M.L., Friedrich M., Fux R., Tscherne A., Kalodimou G., Schmiedel S., Corman V.M., Hesterkamp T., Drosten C., Loeffer F.F., Haagmans B.L., Sutter G., Becker S., Addo M.M.
  Nature Communications 2022 Jul 19;13(1):4182 https://doi.org/10.1038/s4167-022-31557-0

2021

• Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents.
  Bosnjak B., Odak I., Barros-Martins J., Sandrock I., Hammerschmidt S.I., Permanyer M., Patzer G.E., Greorgiev H., Jauregui R.G., Tscherne A., Schwarz J.H., Kalodimou G., Ssebyatika G., Ciurkiewicz M., Willenzon S., Bubke A., Ristenpart J., Ritter C., Tuchel T., Meyer zu Natrup C., Shin D.-L., Clever S., Limpinsel L., Baumgärtner W., Krey T., Volz A., Sutter G., Förster R.
  Frontiers in Immunology 2021 Nov 11, Vol. 12, Article 772240. doi: 10.3389/frmmu.2021.772240e.Collection 2021
• Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination. (pdf, 1,36 MB + 1,46 MB)
  Tscherne A., Schwarz J.H., Rohde C., Kupke A., Kalodimou G., Limpinsel L., Okba N.M.A., Bosnjak B., Sandrock I., Odak I., Halwe S., Sauerhering L., Brosinski K., Liangliang N., Duell E., Jany S., Freudenstein A., Schmidt J., Werner A., Serra M.G., Klüver M., Guggemos W., Seilmaier M., Wendtner C.-M., Förster R., Haagmans B.L., Becker S., Sutter G., Volz A.
  Proc Natl Acad Sci USA 2021 Jul 13;118 e2026207118. doi.org/10.1073/pnas.2026207118

2020

• A Soluble Version of Nipah Virus Glycoprotein G Delivered by Vaccinia Virus MVA Activates Specific CD8 and CD4 T Cells in Mice. (pdf, 2,57 MB)
  Kalodimou G., Veit S., Jany S., Kalinke U., Broder C.C., Sutter G., Volz A.
  Viruses, 2020, 12, 26. doi.10.3390/v12010026